These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36843038)

  • 1. Brolucizumab for Wet Age-Related Macular Degeneration: One-Year Real-World Experience from a Tertiary Center.
    Scupola A; Carlà MM; Boselli F; Giannuzzi F; De Filippis A; Fossataro C; Minnella AM; D'Amico G; Coppola G; Savastano MC; Sammarco MG; Rizzo S
    Ophthalmologica; 2023; 246(1):58-67. PubMed ID: 36843038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of brolucizumab in age-related macular degeneration: A systematic review of real-world studies.
    Baumal CR; Sørensen TL; Karcher H; Freitas RL; Becher A; Balez S; Clemens A; Singer M; Kodjikian L
    Acta Ophthalmol; 2023 Mar; 101(2):123-139. PubMed ID: 36117281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world experience with brolucizumab in neovascular age-related macular degeneration over 2 years: the REBA extension study.
    Bilgic A; Kodjikian L; de Ribot FM; Spitzer MS; Vasavada V; Gonzalez-Cortes JH; Sudhalkar A; Chakraborty S; Mathis T
    Graefes Arch Clin Exp Ophthalmol; 2024 Apr; 262(4):1161-1167. PubMed ID: 38063874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-Life Experience and Predictors of Visual Outcomes with Intravitreal Brolucizumab Switch for Treatment of Neovascular Age-Related Macular Degeneration.
    Cavalleri M; Tombolini B; Sacconi R; Gatta G; Valeri R; Bandello F; Querques G
    Ophthalmologica; 2023; 246(2):158-168. PubMed ID: 37040734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.
    Khanani AM; Brown DM; Jaffe GJ; Wykoff CC; Adiguzel E; Wong R; Meng X; Heier JS;
    Ophthalmology; 2022 Sep; 129(9):974-985. PubMed ID: 35537533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration.
    Enríquez AB; Baumal CR; Crane AM; Witkin AJ; Lally DR; Liang MC; Enríquez JR; Eichenbaum DA
    JAMA Ophthalmol; 2021 Apr; 139(4):441-448. PubMed ID: 33630045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
    Dugel PU; Jaffe GJ; Sallstig P; Warburton J; Weichselberger A; Wieland M; Singerman L
    Ophthalmology; 2017 Sep; 124(9):1296-1304. PubMed ID: 28551167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies.
    Lally DR; Loewenstein A; Arnold JJ; Yang YC; Gedif K; Best C; Patel H; Tadayoni R; Heier JS
    Eye (Lond); 2023 Apr; 37(6):1242-1248. PubMed ID: 35597816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study.
    Bulirsch LM; Saßmannshausen M; Nadal J; Liegl R; Thiele S; Holz FG
    Br J Ophthalmol; 2022 Sep; 106(9):1288-1294. PubMed ID: 33846161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
    Dugel PU; Koh A; Ogura Y; Jaffe GJ; Schmidt-Erfurth U; Brown DM; Gomes AV; Warburton J; Weichselberger A; Holz FG;
    Ophthalmology; 2020 Jan; 127(1):72-84. PubMed ID: 30986442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration.
    Ota H; Takeuchi J; Nakano Y; Horiguchi E; Taki Y; Ito Y; Terasaki H; Nishiguchi KM; Kataoka K
    Jpn J Ophthalmol; 2022 May; 66(3):278-284. PubMed ID: 35233693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal aflibercept efficacy in neovascular age-related macular degeneration with suboptimal response to anti-vascular endothelial growth factor-A therapy.
    Monés J; Biarnés M;
    Eur J Ophthalmol; 2020 Sep; 30(5):1082-1090. PubMed ID: 31088111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization.
    Matsumoto H; Hoshino J; Mukai R; Nakamura K; Akiyama H
    Sci Rep; 2022 May; 12(1):8195. PubMed ID: 35581196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brolucizumab Intravitreal Injections for Wet Age-Related Macular Degeneration: Real-Life Study on a Cohort of Italian Patients.
    Gesualdo C; Rossi S; Iodice CM; Guarino F; Petrella M; D'Agostino FA; Perrotta R; Simonelli F
    Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374314
    [No Abstract]   [Full Text] [Related]  

  • 15. Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration.
    Brynskov T; Munch IC; Larsen TM; Erngaard L; Sørensen TL
    Acta Ophthalmol; 2020 Mar; 98(2):132-138. PubMed ID: 31282617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization.
    Matsumoto H; Hoshino J; Nakamura K; Akiyama H
    Sci Rep; 2023 Feb; 13(1):3249. PubMed ID: 36828853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term outcomes of switching to brolucizumab in japanese patients with neovascular age-related macular degeneration.
    Kitajima Y; Maruyama-Inoue M; Ikeda S; Ito A; Inoue T; Yanagi Y; Kadonosono K
    Jpn J Ophthalmol; 2022 Nov; 66(6):511-517. PubMed ID: 36149566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brolucizumab in age-related macular neovascularization (BRAIN study): Efficacy, optical coherence tomography biomarkers, and safety profile.
    Dabir S; Mohankumar A; Khatri MG; Rajan M
    Indian J Ophthalmol; 2024 Jan; 72(Suppl 1):S33-S36. PubMed ID: 38131539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration.
    Nguyen QD; Das A; Do DV; Dugel PU; Gomes A; Holz FG; Koh A; Pan CK; Sepah YJ; Patel N; MacLeod H; Maurer P
    Ophthalmology; 2020 Jul; 127(7):963-976. PubMed ID: 32107066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brolucizumab in recalcitrant neovascular age-related macular degeneration-real-world data in Chinese population.
    Weng CC; Chi SC; Lin TC; Huang YM; Chou YB; Hwang DK; Chen SJ
    PLoS One; 2024; 19(4):e0301096. PubMed ID: 38564612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.